Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot
Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions
<Composition xmlns="http://hl7.org/fhir">
<id value="179467"/>
<meta>
<versionId value="14"/>
<lastUpdated value="2024-07-29T13:51:43.012Z"/>
<profile
value="http://hl7.org/fhir/uv/ebm/StructureDefinition/recommendation"/>
</meta>
<text>
<status value="extensions"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Composition 179467</b></p><a name="179467"> </a><a name="hc179467"> </a><a name="179467-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 14; Last updated: 2024-07-29 13:51:43+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-recommendation.html">Recommendation</a></p></div><p><b>Artifact Description</b>: </p><div><p>Example of Recommendation Profile of Composition Resource.</p>
</div><p><b>url</b>: <a href="https://fevir.net/resources/Composition/179467">https://fevir.net/resources/Composition/179467</a></p><p><b>identifier</b>: FEvIR Object Identifier/179467</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://fevir.net/resources/CodeSystem/179423 Recommendation}">Recommendation</span></p><p><b>date</b>: 2024-07-29 13:51:43+0000</p><p><b>author</b>: Brian S. Alper</p><p><b>title</b>: Recommendation: ADA Obesity Management Recommendation 8.17</p><p><b>custodian</b>: <a href="Organization-118079.html">Computable Publishing LLC</a></p><h3>RelatesTos</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Type</b></td><td><b>Label</b></td><td><b>Citation</b></td><td><b>ResourceReference</b></td></tr><tr><td style="display: none">*</td><td>Cite As</td><td>Cite as</td><td><div><p>Recommendation: ADA Obesity Management Recommendation 8.17 [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179467. Revised 2024-07-18. Available at: https://fevir.net/resources/Composition/179467. Computable resource at: https://fevir.net/FLI/DocumentForComposition179467.</p>
</div></td><td> </td></tr><tr><td style="display: none">*</td><td>Derived From</td><td>Derived from</td><td><div><p>https://diabetesjournals.org/care/article/44/Supplement_1/S100/30970/8-Obesity-Management-for-the-Treatment-of-Type-2</p>
</div></td><td><a href="Citation-32137.html">JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes</a></td></tr></table></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-description">
<valueMarkdown
value="Example of Recommendation Profile of Composition Resource."/>
</extension>
<url value="https://fevir.net/resources/Composition/179467"/>
<identifier>
<type>
<coding>
<system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
<code value="ACSN"/>
<display value="Accession ID"/>
</coding>
<text value="FEvIR Object Identifier"/>
</type>
<system value="https://fevir.net"/>
<value value="179467"/>
<assigner>
<display value="Computable Publishing LLC"/>
</assigner>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="Recommendation"/>
<display value="Recommendation"/>
</coding>
</type>
<date value="2024-07-29T13:51:43.012Z"/>
<author>
<type value="Practitioner"/>
<display value="Brian S. Alper"/>
</author>
<title value="Recommendation: ADA Obesity Management Recommendation 8.17"/>
<custodian>🔗
<reference value="Organization/118079"/>
<type value="Organization"/>
<display value="Computable Publishing LLC"/>
</custodian>
<relatesTo>
<type value="cite-as"/>
<label value="Cite as"/>
<citation
value="Recommendation: ADA Obesity Management Recommendation 8.17 [Database Entry: FHIR Composition Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 179467. Revised 2024-07-18. Available at: https://fevir.net/resources/Composition/179467. Computable resource at: https://fevir.net/FLI/DocumentForComposition179467."/>
</relatesTo>
<relatesTo>
<type value="derived-from"/>
<label value="Derived from"/>
<citation
value="https://diabetesjournals.org/care/article/44/Supplement_1/S100/30970/8-Obesity-Management-for-the-Treatment-of-Type-2"/>
<resourceReference>🔗
<reference value="Citation/32137"/>
<type value="Citation"/>
<display
value="JournalArticleCitation: ADA 2021 Standards of Medical Care 8. Obesity Management for the Treatment of Type 2 Diabetes"/>
</resourceReference>
</relatesTo>
<section>
<title value="Introduction Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="introduction"/>
<display value="Introduction"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Recommendation Specification"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="recommendation-specification"/>
<display value="Recommendation Specification"/>
</coding>
</code>
<section>
<title value="Recommendation Statement"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="recommendation-statement"/>
<display value="Recommendation Statement"/>
</coding>
<text value="overallSummary"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</div>
</text>
</section>
<section>
<title value="Recommendation Ratings"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="ratings"/>
<display value="Ratings"/>
</coding>
<text value="overallRatings"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">A</div>
</text>
<entry>🔗
<reference value="ArtifactAssessment/179515"/>
<type value="ArtifactAssessment"/>
</entry>
</section>
<section>
<title value="Population"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="population"/>
<display value="Population"/>
</coding>
<text value="population"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">Inclusion Criteria: [[1]] Adults. [[2]] Diagnosed with type 2 diabetes. [[3]] Body Mass Index (BMI) ≥ 30.0 kg/m2 and ≤ 34.9 kg/m2 (BMI 27.5-32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. [[4]] Screened surgical candidates.</div>
</text>
<entry>🔗
<reference value="Group/179511"/>
<type value="Group"/>
<display
value="RecommendationEligibilityCriteria: Eligibility Criteria for Bariatric Surgery (ADA Recommendation 8.17)"/>
</entry>
</section>
<section>
<title value="Action"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="action"/>
<display value="Action"/>
</coding>
<text value="action"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">Metabolic surgery may be considered.</div>
</text>
<entry>🔗
<reference value="PlanDefinition/179554"/>
<type value="PlanDefinition"/>
<display
value="PlanDefinition for Recommendation: ADA Obesity Management Recommendation 8.17"/>
</entry>
</section>
<section>
<title value="Opposite Action"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="opposite-action"/>
<display value="Opposite Action"/>
</coding>
<text value="oppositeAction"/>
</code>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
</section>
<section>
<title value="Justification"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="justification"/>
<display value="Justification"/>
</coding>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p><b>Title: </b>Justification for Recommendation: ADA Obesity Management Recommendation 8.17</p><br/><p><b>Justification for Recommendation: </b>Recommendation: ADA Obesity Management Recommendation 8.17</p><br/><table><tr><th>Concept</th><th>Summary</th><th>Rating</th></tr><tr><td>Recommendation Specification (coded as: RJCS-content0 from https://fevir.net/resources/CodeSystem/27834); Recommendation Specification (coded as: recommendation-specification from https://fevir.net/resources/CodeSystem/179423)</td><td>8.17 Metabolic surgery may be considered as an option to treat type 2 diabetes in adults with BMI 30.0–34.9 kg/m2 (27.5–32.4 kg/m2 in Asian Americans) who do not achieve durable weight loss and improvement in comorbidities (including hyperglycemia) with nonsurgical methods. A</td><td>undefined</td></tr><tr><td>Rating System (coded as: rating-system from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>ADA Level of Evidence</td></tr><tr><td>Strength of Recommendation (coded as: RJCS-1000 from https://fevir.net/resources/CodeSystem/27834); Strength of Recommendation (coded as: strength-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Direction of Recommendation (coded as: RJCS-1014 from https://fevir.net/resources/CodeSystem/27834); Direction of Recommendation (coded as: direction-of-recommendation from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>Favors intervention (coded as: RJCS-2021 from https://fevir.net/resources/CodeSystem/27834)</td></tr><tr><td>Ratings (coded as: ratings from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>A</td></tr><tr><td>Evidence (coded as: RJCS-content1 from https://fevir.net/resources/CodeSystem/27834); Evidence (coded as: evidence from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Summary of Findings (coded as: summary-of-findings from https://fevir.net/resources/CodeSystem/179423)</td><td>ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</td><td>undefined</td></tr><tr><td>Desirable Effects (coded as: RJCS-1004 from https://fevir.net/resources/CodeSystem/27834); Desirable Effects (coded as: desirable-effects from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Undesirable Effects (coded as: RJCS-1005 from https://fevir.net/resources/CodeSystem/27834); Undesirable Effects (coded as: undesirable-effects from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.<br/>In extended follow-up of obese adults with type 2 diabetes randomized to adding gastric bypass compared with lifestyle and intensive medical management alone, there remained a significantly better composite triple end point in the surgical group at 5 years. However, because the effect size diminished over 5 years, further follow-up is needed to understand the durability of the improvement.</td><td>undefined</td></tr><tr><td>Net Effect (coded as: RJCS-1007 from https://fevir.net/resources/CodeSystem/27834); Net Effect (coded as: net-effect from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Values/Preferences (coded as: RJCS-1006 from https://fevir.net/resources/CodeSystem/27834); Preferences (coded as: preferences from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Discussion (coded as: discussion from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Judgments (coded as: RJCS-content2 from https://fevir.net/resources/CodeSystem/27834); Judgments (coded as: judgments from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Justification (coded as: justification from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Problem Importance (coded as: RJCS-1003 from https://fevir.net/resources/CodeSystem/27834); Problem Importance (coded as: problem-importance from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Resources/Costs (coded as: RJCS-1008 from https://fevir.net/resources/CodeSystem/27834); Costs (coded as: costs from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Cost-effectiveness (coded as: RJCS-1009 from https://fevir.net/resources/CodeSystem/27834); Cost-effectiveness (coded as: cost-effectiveness from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Equity (coded as: RJCS-1010 from https://fevir.net/resources/CodeSystem/27834); Equity (coded as: equity from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Acceptability (coded as: RJCS-1011 from https://fevir.net/resources/CodeSystem/27834); Acceptability (coded as: acceptability from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Feasibility (coded as: RJCS-1012 from https://fevir.net/resources/CodeSystem/27834); Feasibility (coded as: feasibility from https://fevir.net/resources/CodeSystem/179423)</td><td>undefined</td><td>undefined</td></tr><tr><td>Competing Interests (coded as: RJCS-1002 from https://fevir.net/resources/CodeSystem/27834); Competing Interests (coded as: competing-interests from https://fevir.net/resources/CodeSystem/179423)</td><td>All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</td><td>undefined</td></tr></table><br/></div>
</text>
<entry>🔗
<reference value="ArtifactAssessment/179515"/>
<type value="ArtifactAssessment"/>
<display
value="Justification for Recommendation: ADA Obesity Management Recommendation 8.17"/>
</entry>
</section>
<section>
<title value="Considerations"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="considerations"/>
<display value="Considerations"/>
</coding>
</code>
<section>
<title value="Overall Considerations Summary"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="summary"/>
<display value="Summary"/>
</coding>
<text value="overallConsiderationsSummary"/>
</code>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Subgroup Considerations Summary"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="subgroup-considerations"/>
<display value="Subgroup Considerations"/>
</coding>
<text value="subgroupConsiderationsSummary"/>
</code>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Implementation Considerations Summary"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="implementation-considerations"/>
<display value="Implementation Considerations"/>
</coding>
<text value="implementationConsiderationsSummary"/>
</code>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Monitoring Considerations Summary"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="monitoring-considerations"/>
<display value="Monitoring Considerations"/>
</coding>
<text value="monitoringConsiderationsSummary"/>
</code>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Competing Interests Summary"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="competing-interests"/>
<display value="Competing Interests"/>
</coding>
<text value="competingInterestsSummary"/>
</code>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml">All members of the PPC are required to disclose potential conflicts of interest with industry and other relevant organizations. These disclosures are discussed at the outset of each Standards of Care revision meeting. Members of the committee, their employers, and their disclosed conflicts of interest are listed in 'Disclosures: Standards of Medical Care in Diabetes—2021' (https://doi.org/10.2337/dc21-SPPC). The ADA funds development of the Standards of Care out of its general revenues and does not use industry support for this purpose. NOTE: The disclosed conflicts of interest was not found at the suggested URL</div>
</text>
<entry>🔗
<reference value="ArtifactAssessment/179515"/>
<type value="ArtifactAssessment"/>
</entry>
</section>
<section>
<title value="Research Priorities Summary"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="research-considerations"/>
<display value="Research Considerations"/>
</coding>
<text value="researchConsiderationsSummary"/>
</code>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
</section>
<section>
<title value="Methods Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="methods"/>
<display value="Methods"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Evidence"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="evidence"/>
<display value="Evidence"/>
</coding>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">ADA Level of Evidence A. A substantial body of evidence has now been accumulated, including data from numerous randomized controlled (nonblinded) clinical trials, demonstrating that metabolic surgery achieves superior glycemic control and reduction of cardiovascular risk factors in patients with type 2 diabetes and obesity compared with various lifestyle/medical interventions.</div>
</text>
<entry>🔗
<reference value="ArtifactAssessment/179515"/>
<type value="ArtifactAssessment"/>
</entry>
</section>
<section>
<title value="Discussion"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="discussion"/>
<display value="Discussion"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="References Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="references"/>
<display value="References"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Competing Interests Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="competing-interests"/>
<display value="Competing Interests"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Acknowledgements Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="acknowledgements"/>
<display value="Acknowledgements"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
<section>
<title value="Appendices Section"/>
<code>
<coding>
<system value="https://fevir.net/resources/CodeSystem/179423"/>
<code value="appendices"/>
<display value="Appendices"/>
</coding>
</code>
<text>
<status value="empty"/>
<div xmlns="http://www.w3.org/1999/xhtml">[No data.]</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="notstarted"/>
<display value="Not Started"/>
</coding>
</emptyReason>
</section>
</Composition>
IG © 2024+ HL7 International / Clinical Decision Support. Package hl7.fhir.uv.ebm#2.0.0-ballot based on FHIR 6.0.0-ballot2. Generated 2024-12-19
Links: Table of Contents |
QA Report
| Version History |
|
Propose a change